Hims TRT & Testosterone Review
From $4 · Free consult · 4.2★ on Trustpilot · All 50 States
7,811 verified reviews
Lowest-priced enclomiphene TRT-alternative at scale — fits a narrow case, not full testosterone replacement.
Is Hims the right fit for you?
Who it's for
- Men with mild low T (total T in the 250–400 ng/dL range) who haven't tried first-line interventions and want a fertility-preserving alternative to standard TRT
- Fertility-preservation candidates who want to maintain natural testosterone production (enclomiphene stimulates the HPT axis rather than replacing testosterone)
- Hims subscribers already on ED / hair loss / weight loss who want to add TRT-category treatment under their existing account
- Price-sensitive shoppers comfortable with the modality limitation ($99/month is the lowest-priced TRT-category entry in the market)
Who it's not for
- Anyone needing INJECTABLE testosterone replacement — Hims is enclomiphene-only today (injectable TRT planned for 2026)
- Men with moderate to severe hypogonadism — enclomiphene works for mild cases responding to HPT-axis stimulation, not for cases requiring exogenous T
- Patients with primary hypogonadism (testicular failure) where the HPT axis cannot respond to enclomiphene
- Anyone with prior cancellation friction on Hims subscriptions — the persistent customer-service complaint pattern is real and worth weighing
Your first 3 months with Hims
Same-day intake on the Hims platform — short questionnaire covering symptoms, medical history, and current medications. No upfront cost, free consultation. The TRT product flow is more abbreviated than dedicated TRT clinics because enclomiphene prescribing has narrower screening requirements than injectable TRT.
Video or async consult with a licensed physician. Lab order issued covering hormone panel (total T, free T, LH, FSH, estradiol) — the panel is more focused than what a dedicated TRT clinic might pull, because enclomiphene prescribing requires specific hormone-axis markers rather than the broader workup needed for injectable TRT. Local LabCorp or Quest draw; results in 2–3 business days.
Lab review confirms candidacy for enclomiphene. First prescription shipped 2–5 days from script approval (Hims shipping is faster than many competitors). Begin oral enclomiphene typically at 12.5–25 mg every other day. Effects on energy and libido often emerge by week 3–4; testosterone level changes typically measurable by week 6–8.
Follow-up labs at 8–12 weeks measure hormone-axis response — total T, free T, LH, FSH. If responding (target total T typically 500–800 ng/dL on enclomiphene), maintain dose. If not responding adequately, the conversation shifts to whether injectable TRT through a dedicated clinic is the appropriate next step. Hims will refer out for cases that need exogenous testosterone (since they don't yet offer injectable).
Hims vs the alternatives
[PeterMD](/online-providers/trt-testosterone/petermd) offers the full range of TRT modalities — injectable testosterone cypionate (the standard of care for full TRT), oral enclomiphene, and topical cream. Hims is enclomiphene-only for TRT today. PeterMD is also TRT-focused as a primary product line; Hims-TRT is one of many categories Hims serves. For cost-comparable enclomiphene only, the two are close ($99/mo Hims vs PeterMD's $278/2-month enclomiphene supply — Hims is cheaper per month). For anyone needing injectable TRT or the option to switch modalities, PeterMD wins by default. AHF rates PeterMD 4.3 and Hims (TRT) 3.9 — gap reflects the modality limitation more than legitimacy concerns.
[Marek Health](/online-providers/trt-testosterone/marek-health) is the premium-concierge hormone-optimization service — comprehensive hormone panel (full thyroid, adrenal, advanced lipids), longer prescriber relationships, and structured monitoring. For TRT specifically, Marek prescribes injectable testosterone where clinically appropriate plus the broader hormone-optimization context. Hims is enclomiphene-only at the lowest entry pricing. AHF rates Marek 4.4 and Hims (TRT) 3.9 — gap reflects modality breadth + clinical depth vs lowest-cost narrow-use-case access. Pick Marek if you want injectable TRT in a clinical-optimization context. Pick Hims if you want enclomiphene specifically at the lowest price.
Honest Breakdown
What Works Well
- Extremely affordable ED meds starting at $4/dose
- Massive scale with 2.5M+ active subscribers
- Free online consultations included
- Publicly traded company (NYSE: HIMS) - established trust
- Available in all 50 states
- Wide range of treatments in one platform
- Discreet packaging and fast shipping
- Chewable ED options (Hard Mints) available
Watch Points
- Subscription cancellation can be difficult
- Mixed customer service reviews
- No injectable TRT yet (coming 2026)
- Uses compounded GLP-1 (not brand-name Ozempic/Wegovy)
What people actually ask about Hims
Yes — Hims operates as a publicly traded US telehealth platform (NYSE: HIMS) with 2.5M+ subscribers and $2.35B in 2025 revenue. Licensed physicians prescribe in each state served, FDA-registered pharmacies dispense medications, and the platform clears every basic legitimacy check for telehealth prescribing. The watch point isn't legitimacy — it's the modality. Hims-TRT today is enclomiphene-only, which is legitimate medicine for the right candidate but not what most users mean when they search for "TRT review." Editorial honesty requires being clear that this is a fertility-preserving alternative to TRT, not testosterone replacement itself.
Ready to start with Hims?
Free consultation. Independently reviewed. Board-certified physicians.
Get Free ConsultationSecure telemedicine · HIPAA compliant · Cancel anytime